Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Linaclotide 290 micrograms

Preclinical

UUniversity of Nottingham

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cystic Fibrosis (CF)Not yet recruiting

Cystic Fibrosis (CF)Preclinical

Not yet recruiting

Timeline

Expected Milestones

Q3 2027

PreclinicalNot yet recruiting

Cystic Fibrosis (CF)

NCT07780344

Clinical

Trials by Indication[1]

Cystic Fibrosis (CF)1 trial

A Feasibility Study Evaluating MRI Parameters as Biomarkers of the Effect of a Secretagogue in Cystic Fibrosis (FEMPTO)

Not yet recruiting·UUniversity of Nottingham·Preclinical·NCT07780344·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Linaclotide 290 micrograms. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Linaclotide 290 micrograms. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Nottingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: UUniversity of Nottingham

Related News